<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "JATS-journalpublishing1.dtd">
<article article-type="review-article" dtd-version="1.0" xml:lang="hr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LV</journal-id>
<journal-id journal-id-type="nlm-ta">Lijec Vjesn</journal-id>
<journal-title-group>
<journal-title>Lijecnicki Vjesnik</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Lijec. Vjesn.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="ppub">0024-3477</issn>
<issn pub-type="epub">1849-2177</issn>
<publisher><publisher-name>Croatian Medical Association</publisher-name></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">LV-143-120</article-id>
<article-id pub-id-type="doi">10.26800/LV-143-3-4-8</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group>
</article-categories>
<title-group>
<article-title>Razumijevanje, prevencija i lije&#x010D;enje <italic>refeeding</italic>-sindroma: uloga tiamina</article-title>
<trans-title-group xml:lang="en">
<trans-title>Understanding, prevention and treatment of refeeding syndrome. The role of thiamine.</trans-title>
</trans-title-group>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4310-7580</contrib-id><name><surname>Ljubas Kele&#x010D;i&#x0107;</surname><given-names>Dina</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vrane&#x0161;i&#x0107; Bender</surname><given-names>Darija</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Krznari&#x0107;</surname><given-names>&#x017D;eljko</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<aff id="aff1"><label>1</label>Odjel za klini&#x010D;ku prehranu, Klinika za unutarnje bolesti, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb</aff>
<aff id="aff2"><label>2</label>Zavod za gastroenterologiju i hepatologiju, Klinika za unutarnje bolesti, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb</aff>
<aff id="aff3"><label>3</label>Medicinski fakultet Sveu&#x010D;ili&#x0161;ta u Zagrebu</aff>
</contrib-group>
<author-notes>
<corresp id="cor1">Adresa za dopisivanje: Dina Ljubas Kele&#x010D;i&#x0107;, <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-4310-7580">https://orcid.org/0000-0003-4310-7580</ext-link> Odjel za klini&#x010D;ku prehranu, Klinika za unutarnje bolesti, Klini&#x010D;ki bolni&#x010D;ki centar Zagreb, Ki&#x0161;pati&#x0107;eva 12, 10000 Zagreb; e-po&#x0161;ta: <email xlink:href="ljubas.dina@gmail.com">ljubas.dina@gmail.com</email></corresp></author-notes>
<pub-date pub-type="epub-ppub"><month>04</month><year>2021</year></pub-date>
<volume>143</volume>
<issue>3-4</issue>
<fpage>120</fpage>
<lpage>129</lpage>
<permissions>
<copyright-year>2021</copyright-year>
<copyright-holder>Croatian Medical Association</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" specific-use="CC BY-NC-ND 4.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (CC BY-NC-ND) 4.0 License.</license-p></license>
</permissions>
<abstract>
<title>SA&#x017D;ETAK</title>
<sec><title>Refeeding</title><p>sindrom (RFS) je ozbiljna i potencijalno fatalna komplikacija koja se javlja u bolesnika s ozbiljnom pothranjenosti razli&#x010D;ite etiologije nakon ponovnog, nekontroliranog uvo&#x0111;enja prehrane, osobito ugljikohidrata. Nastanak komplikacija RFS-a, koje mogu zahvatiti bilo koji organski sustav ili vi&#x0161;e njih uslijed ozbiljnog elektrolitskog disbalansa, uvjetovan je brzim metaboli&#x010D;kim promjenama koje nastaju prilikom prelaska organizma iz katabolizma u anabolizam te unutarstani&#x010D;nom deplecijom fosfora, kalija, magnezija te vitamina i mineralnih tvari. Naj&#x010D;e&#x0161;&#x0107;e komplikacije RFS-a vezane uz nedostatak vitamina odnose se na nedostatak tiamina. Zbog svoje klju&#x010D;ne koenzimske uloge u metabolizmu ugljikohidrata i aminokiselina razgranatih lanaca, tiamin je va&#x017E;an &#x010D;imbenik za odr&#x017E;avanje normalne funkcije prije svega cerebralnog metabolizma. Razumijevanje temeljnih biokemijskih procesa tijekom gladovanja te posljedi&#x010D;no mehanizama i &#x010D;imbenika koji utje&#x010D;u na metaboli&#x010D;ke promjene tijekom RFS-a va&#x017E;no je radi pravovremenog prepoznavanja bolesnika u riziku i prevencije RFS-a te brojnih klini&#x010D;kih komplikacija koje nosi bez obzira na modalitet nutritivne potpore.</p></sec>
</abstract>
<trans-abstract xml:lang="en">
<title>SUMMARY</title>
<p>Refeeding syndrome (RFS) is a serious and potentially fatal complication that occurs in patients with severe malnutrition of various etiologies after repeated, uncontrolled introduction of a diet, especially carbohydrates. Complications of RFS develop due to rapid metabolic changes that occur during the switch from catabolism to anabolism, and cellular depletion of phosphorus, potassium, magnesium and micronutrients, and can affect one or more organ systems. Most of RFS complications associated with vitamin deficiency are related to thiamine deficiency. Due to its coenzyme role in the metabolism of carbohydrates and branched chain amino acids, thiamine is an important factor in maintaining the normal function primarily of cerebral energy metabolism. Understanding the basic biochemistry during starvation, and consequently the mechanisms and factors influencing metabolic changes during RFS, is important for timely identification of patients at risk and prevention of RFS and also many clinical complications it can cause regardless of nutritional support modality.</p>
</trans-abstract>
<kwd-group kwd-group-type="author"><kwd>Deskriptori REALIMENTACIJSKI SINDROM &#x2013; komplikacije, lije&#x010D;enje, patofiziologija, prevencija</kwd><kwd>MALNUTRICIJA &#x2013; lije&#x010D;enje, metabolizam</kwd><kwd>NUTRITIVNA POTPORA &#x2013; ne&#x017E;eljeni u&#x010D;inci</kwd><kwd>HIPOFOSFATEMIJA &#x2013; etiologija, komplikacije, lije&#x010D;enje</kwd><kwd>TIAMIN &#x2013; fiziologija, terapijska uporaba</kwd><kwd>NEDOSTATAK TIAMINA &#x2013; etiologija, komplikacije, lije&#x010D;enje</kwd><kwd>NEDOSTATAK MAGNEZIJA &#x2013; lije&#x010D;enje</kwd><kwd>HIPOKALEMIJA &#x2013; lije&#x010D;enje</kwd><kwd>WERNICKEOVA ENCEFALOPATIJA &#x2013;etiologija, lije&#x010D;enje, patofiziologija</kwd></kwd-group>
<kwd-group kwd-group-type="translator" xml:lang="en"><title>Descriptors </title><kwd>REFEEDING SYNDROME &#x2013; complications, physiopathology, prevention and control, therapy</kwd><kwd>MALNUTRITION &#x2013; metabolism, therapy</kwd><kwd>NUTRITIONAL SUPPORT &#x2013; adverse effects</kwd><kwd>HYPOPHOSPHATEMIA &#x2013; complications, etiology, therapy</kwd><kwd>THIAMINE &#x2013; physiology, therapeutic use</kwd><kwd>THIAMINE DEFICIENCY &#x2013; complications, etiology, therapy</kwd><kwd>MAGNESIUM DEFICIENCY &#x2013; therapy</kwd><kwd>HYPOKALEMIA &#x2013; therapy</kwd><kwd>WERNICKE ENCEPHALOPATHY &#x2013; etiology, physiopathology, therapy</kwd></kwd-group>
</article-meta>
</front>
<body>
<p><italic>Refeeding</italic>-sindrom (RFS) definira se kao ozbiljan i potencijalno fatalan poreme&#x0107;aj elektrolita i tjelesnih teku&#x0107;ina koji nastaje uslijed metaboli&#x010D;kih abnormalnosti kod pothranjenih bolesnika nakon ponovnog uvo&#x0111;enja prehrane, bilo da se radi o oralnom, enteralnom ili parenteralnom putu primjene. (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) RFS je prvi put opisan nakon Drugoga svjetskog rata kod pothranjenih zarobljenika koji su umirali od zatajenja srca kada im je nakon dugotrajnog gladovanja ponovno uvedeno hranjenje. (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>) Danas je patofiziologija RFS-a dobro razja&#x0161;njena, a podrazumijeva hormonalne i metaboli&#x010D;ke promjene uslijed naglog prelaska organizma iz dugotrajnog katabolizma u anabolizam koje mogu dovesti do brojnih komplikacija kod pothranjenih bolesnika. Ozbiljnije komplikacije RFS-a mogu zahva&#x0107;ati razli&#x010D;ite organske sustave iako se naj&#x010D;e&#x0161;&#x0107;e odra&#x017E;avaju na kardiovaskularni (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>) i &#x017E;iv&#x010D;ani sustav, (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) te ako se na vrijeme ne prepoznaju mogu dovesti i do smrtnog ishoda. Hipofosfatemija je glavno obilje&#x017E;je RFS-a, a obi&#x010D;no nastaje izme&#x0111;u drugog i &#x010D;etvrtog dana od uvo&#x0111;enja nutritivne potpore. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Nadalje, nedostatak vitamina i mineralnih tvari, va&#x017E;nih kofaktora razli&#x010D;itih enzima koji sudjeluju u metabolizmu, mogu izazvati ili pogor&#x0161;ati ve&#x0107; postoje&#x0107;e komplikacije RFS-a. Ovdje je tiamin osobito va&#x017E;an zbog svoje neizostavne uloge u metabolizmu ugljikohidrata i aminokiselina razgranatog lanca, budu&#x0107;i da nedostatak istoga mo&#x017E;e izazvati ozbiljne neurolo&#x0161;ke komplikacije kao &#x0161;to su Wernickeova encefalopatija i Wernicke-Korsakoffljev sindrom te laktatnu acidozu kao manje poznatu komplikaciju. (<xref ref-type="bibr" rid="r6"><italic>6</italic></xref>)</p>
<p>Incidencija RFS-a u razli&#x010D;itim bolni&#x010D;kim populacijama varira od 0,43% do 34% (<xref ref-type="bibr" rid="r7"><italic>7</italic></xref>-<xref ref-type="bibr" rid="r9"><italic>9</italic></xref>) ovisno o tome promatra li se hipofosfatemija ili pothranjenost kao glavni &#x010D;imbenik rizika za nastanak RFS-a. Kod bolesnika koji primaju artificijelnu nutritivnu potporu (enteralnu ili parenteralnu prehranu), u&#x010D;estalost RFS-a je 3%. (<xref ref-type="bibr" rid="r5"><italic>5</italic></xref>) Iako se primjena glukoze uz parenteralnu prehranu u literaturi navodi kao naj&#x010D;e&#x0161;&#x0107;i uzrok nastanka RFS-a, prema nekim radovima u&#x010D;estalost <italic>refeeding</italic> hipofosfatemije ve&#x0107;a je kod enteralnog nego parenteralnog hranjenja. (<xref ref-type="bibr" rid="r10"><italic>10</italic></xref>) &#x010C;imbenici rizika za nastanak RFS-a su pothranjenost, nenamjeran gubitak na tjelesnoj masi, minimalan ili nedovoljan peroralni unos hrane kroz dulje vremensko razdoblje te inicijalno niske serumske koncentracije kalija, fosfata ili magnezija prije uvo&#x0111;enja nutritivne potpore. Op&#x0107;enito, mo&#x017E;emo re&#x0107;i da razli&#x010D;ite bolesti (kroni&#x010D;ni alkoholizam, anoreksija nervoza, tumori, kroni&#x010D;na disfagija, depresija kod starijih bolesnika i dr.) i stanja (protrahirano povra&#x0107;anje ili proljev, zatajenje ili upala probavne cijevi i dr.) kod kojih dolazi do smanjenog unosa, apsorpcije i/ili gubitka nutrijenata, predstavljaju potencijalni rizik za nastanak RFS-a. (<xref ref-type="bibr" rid="r11"><italic>11</italic></xref>)</p>
<p>Cilj je ovoga rada razjasniti biokemijske i patofiziolo&#x0161;ke procese u pozadini nastanka RFS-a, pomo&#x0107;i lije&#x010D;nicima u prepoznavanju bolesnika u riziku nastanka <italic>refeeding</italic>-sindroma te prevenciji i lije&#x010D;enju istoga.</p>
<sec sec-type="other1">
<title>Patofiziologija <italic>refeeding</italic>-sindroma</title>
<p>Patofiziologija RFS-a uklju&#x010D;uje brze metaboli&#x010D;ke promjene u bolesnika s naru&#x0161;enim nutritivnim statusom uslijed prelaska organizma iz katabolizma u anabolizam. Sni&#x017E;enje serumskih vrijednosti elektrolita, osobito fosfata, kalija i magnezija doga&#x0111;a se zbog brzog ulaska ovih elektrolita zajedno s glukozom u stanice, uvjetovanog hormonskim promjenama, prije svega inzulina i glukagona.</p>
<p>Metabolizam tijekom gladovanja. Tijekom gladovanja izlu&#x010D;ivanje inzulina se smanjuje kao odgovor na smanjeni unos ugljikohidrata, a pove&#x0107;ava se lu&#x010D;enje glukagona koji poti&#x010D;e razgradnju, a inhibira sintezu glikogena pokretanjem cikli&#x010D;ke AMP kaskade koja dovodi do fosforilacije i aktivacije fosforilaze i inhibicije glikogen-sintaze. Glukagon tako&#x0111;er inhibira sintezu masnih kiselina smanjenjem proizvodnje piruvata i smanjenjem aktivnosti acetil-CoA karboksilaze te stimulira glukoneogenezu u jetri i blokira glikolizu. Kod niske razine glukoze u krvi, mi&#x0161;i&#x0107;i i jetra koriste masne kiseline kao osnovno metaboli&#x010D;ko gorivo s obzirom na to da se glikogen iz jetre i mi&#x0161;i&#x0107;a potro&#x0161;i ve&#x0107; nakon 24 sata gladovanja. U po&#x010D;etku gladovanja inicijalno zapo&#x010D;inje i mobilizacija i katabolizam bjelan&#x010D;evina koji se zatim brzo smanjuje jer se najve&#x0107;i dio energije dobiva iz slobodnih masnih kiselina i ketonskih tijela. Bjelan&#x010D;evine se najvi&#x0161;e tro&#x0161;e u prvoj i zadnjoj fazi gladovanja. (<xref ref-type="bibr" rid="r12"><italic>12</italic></xref>) Glukoneogeneza se usporava, a time se smanjuje i mogu&#x0107;nost nastanka glukoze iz odre&#x0111;enih aminokiselina i laktata, pa glicerol oslobo&#x0111;en iz triacilglicerola postaje glavni izvor za sintezu glukoze u jetri (jetra jedina sadr&#x017E;i enzim glicerol kinazu). Pove&#x0107;ana razgradnja triacilglicerola u masnome tkivu uz glicerol osloba&#x0111;a i slobodne masne kiseline koje se dalje metaboliziraju u jetri. Akumuliranje acetil-CoA iz slobodnih masnih kiselina u jetri smanjuje se ketogenezom kako bi se proizvela ketonska tijela acetoacetat i &#x03B2;-hidroksibutirat, oblici masti topljivi u vodi koji se ponovno metaboliziraju u acetil-CoA i koriste za proizvodnju energije za razli&#x010D;ita tkiva kao &#x0161;to su mi&#x0161;i&#x0107;i, mozak, bubrezi (<xref ref-type="fig" rid="f1">Figure 1</xref>.). (<xref ref-type="bibr" rid="r13"><italic>13</italic></xref>) Mozak prvih nekoliko dana dobiva glukozu iz glicerola, a zatim se prilago&#x0111;ava uporabi ketonskih tijela koja nastaju iz masti u jetri te postaju glavno stani&#x010D;no gorivo. Na taj na&#x010D;in &#x0161;tedi se glukoza u krvi za uporabu crvenih krvnih stanica koje se oslanjaju isklju&#x010D;ivo na glukozu za proizvodnju energije.</p>
<fig id="f1" position="float" fig-type="figure"><label>Figure 1</label><caption><p>Metabolism during starvation in liver (A), muscle (B) and adipose tissue (C). Cell changes during starvation (D). ATP, adenosine triphosphate; CLK, citric acid cycle; G6P, glucose-6-phosphate; MK, fatty acids; P, phosphate; Mg, magnesium; B1, vitamin B1 (thiamine)</p></caption><graphic xlink:href="LV-143-120-f1"></graphic></fig>
<p>Smanjena upotreba glukoze u mozgu smanjuje potrebu i za jetrenom glukoneogenezom iz mi&#x0161;i&#x0107;a i time se neizravno &#x0161;titi mi&#x0161;i&#x0107;ne proteine. Glavno obilje&#x017E;je prolongiranog gladovanja je ketoza, a aceton koji nastaje spontano razgradnjom acetoacetata daje dah po vo&#x0107;nom mirisu, karakteristi&#x010D;an kod dugotrajnog gladovanja. (<xref ref-type="bibr" rid="r14"><italic>14</italic></xref>)</p>
<p>Uloga tiamina. Tiamin, vitamin B1 ili aneurin (stariji naziv, tzv. &#x201E;antineuritski&#x201C; vitamin) (<xref ref-type="bibr" rid="r15"><italic>15</italic></xref>) ima va&#x017E;nu ulogu u metabolizmu ugljikohidrata i aminokiselina razgranatih lanaca, zbog &#x010D;ega je neophodan nutrijent u stanicama razli&#x010D;itih tkiva, osobito mozga koji ima velike potrebe za glukozom kao glavnim metaboli&#x010D;kim supstratom. U svom aktivnom obliku pirofosfata, tiamin je kofaktor enzima piruvat dehidrogenaze, &#x03B1;-ketoglutarat dehidrogenaze, transketolaze i &#x03B1;-keto kiselina dehidrogenaze uklju&#x010D;enih u metaboli&#x010D;ke puteve u kojima nastaje adenozin-trifosfat (ATP), nikotinamid adenin dinukleotid fosfat (NADPH) i riboza-5-fosfat putem kojih nastaje energija u stanicama te se sintetiziraju aminokiseline, nukleinske kiseline i masne kiseline (<xref ref-type="fig" rid="f2">Figure 2</xref>.). (<xref ref-type="bibr" rid="r16"><italic>16</italic></xref>)</p>
<fig id="f2" position="float" fig-type="figure"><label>Figure 2</label><caption><p>The role of thiamine in the metabolism of carbohydrates and branched chain amino acids. TPP, thiamine pyrophosphate; CLK, citric acid cycle</p></caption><graphic xlink:href="LV-143-120-f2"></graphic></fig>
<p>Zalihe tiamina, primarno u jetri te ne&#x0161;to u skeletnim mi&#x0161;i&#x0107;ima, ograni&#x010D;ene su (ukupno oko 30 mg), a nedostatak tiamina mo&#x017E;e nastati ve&#x0107; nakon 2&#x2013;3 tjedna u slu&#x010D;aju prehrane izrazito siroma&#x0161;ne tiaminom, gladovanja, kroni&#x010D;nog alkoholizma, nekih tumora i drugih klini&#x010D;kih bolesti i stanja. Organizam ne mo&#x017E;e sintetizirati tiamin te ga je potrebno svakodnevno unositi putem hrane ili dodataka prehrani u dnevnoj dozi od 1,1 &#x2013; 1,2 mg kod odrasle populacije. (<xref ref-type="bibr" rid="r17"><italic>17</italic></xref>) Tiamin pirofosfat je aktivni oblik tiamina koji sudjeluje u metabolizmu ugljikohidrata kao koenzim vi&#x0161;ekomponentnim enzimskim kompleksima. Piruvat dehidrogenaza i &#x03B1;-ketoglutarat dehidrogenaza su enzimi koji kataliziraju dekarboksilaciju piruvata, &#x03B1;-ketoglutarata i aminokiselina razgranatog lanca do acetil-CoA, sukcinil-CoA i derivata aminokiselina razgranatog lanca kao produkata koji su povezani s Krebsovim ciklusom, a s ciljem nastanka energije iz hrane. Metabolizam aminokiselina leucina, izoleucina i valina dodatno doprinosi proizvodnji kolesterola te donira du&#x0161;ik za sintezu neurotransmitera, glutamata i &#x03B3;-aminobutilne kiseline (GABA). Transketolaza katalizira pentoza metaboli&#x010D;ki put pentoza fosfata u citosolu koji je va&#x017E;an za nastanak riboza-5-fosfata potrebnog za sintezu nukleinskih kiselina, a djelomi&#x010D;no je povezana i s glikolizom. (<xref ref-type="bibr" rid="r18"><italic>18</italic></xref>) Budu&#x0107;i da se aktivnost enzima transketolaze brzo smanjuje kod nedostatka tiamina, te s obzirom na to da se za razliku od ostalih enzima ovisnih o tiaminu ona nalazi i u crvenim krvnim stanicama, mjerenje njezine aktivnosti u crvenim krvnim stanicama koristi se i za procjenu nutritivnog statusa tiamina. (<xref ref-type="bibr" rid="r19"><italic>19</italic></xref>) Tiamin ima klju&#x010D;nu ulogu u cerebralnom metabolizmu, jer se mozak primarno koristi glukozom kao glavnim supstratom za dobivanje energije, ali i zbog sinteze neurotransmitera. Enzimi ovisni o tiaminu nalaze se u sredi&#x0161;njem i perifernom &#x017E;iv&#x010D;anom sustavu, a oko 80% tiamina tro&#x0161;i se samo na aktivnost enzima u mozgu. Osim koenzimske uloge, tiamin ima i strukturnu ulogu u &#x017E;iv&#x010D;anom tkivu odnosno interakciji s biolo&#x0161;kim membranama uklju&#x010D;uju&#x0107;i membrane aksona, mitohondrija i sinapsi, zatim ima ulogu u sinapti&#x010D;kom prijenosu, stani&#x010D;noj diferencijaciji, stvaranju sinapsi, aksonskom rastu i mijelogenezi. (<xref ref-type="bibr" rid="r20"><italic>20</italic></xref>)</p>
<p>Ponovno uvo&#x0111;enje prehrane nakon gladovanja. Katabolizam masti i proteina tijekom gladovanja s vremenom dovodi do unutarstani&#x010D;nog gubitka elektrolita, osobito fosfata koji ima i klju&#x010D;nu ulogu u sintezi molekule ATP-a te kalija i magnezija. Normalne serumske vrijednosti ovih elektrolita (organizam bez obzira na tjelesne promjene odr&#x017E;ava serumske koncentracije elektrolita) kod pothranjenih bolesnika prije po&#x010D;etka hranjenja &#x010D;esto se pogre&#x0161;no tuma&#x010D;e te se bolesnike ne svrstava u rizi&#x010D;nu skupinu. Me&#x0111;utim, kad se po&#x010D;ne uvoditi prehrana, osobito glukoza, zbog lu&#x010D;enja inzulina dolazi do naglog prelaska iz metabolizma masti u metabolizam ugljikohidrata, glukoza ulazi u stanicu i za sobom povla&#x010D;i fosfate (za sintezu ATP-a iz glukoze), magnezij i kalij, &#x0161;to se o&#x010D;ituje sni&#x017E;enjem serumskih vrijednosti ovih elektrolita u 24 &#x2013; 72 h. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>) Inzulin aktivira apsorpciju kalija u stanice putem natrij-kalijeve ATP-aze, koja tako&#x0111;er prenosi glukozu u stanice te pove&#x0107;ava permeabilnost ostalih stanica za magnezij i fosfat. Zbog osmotske neutralnosti i pove&#x0107;anog lu&#x010D;enja inzulina dolazi do retencije natrija i vode, a ponovno aktiviranje metaboli&#x010D;kih puteva ovisnih o ugljikohidratima dodatno pove&#x0107;ava potra&#x017E;nju za tiaminom. Hipofosfatemija, hipokalijemija i hipomagnezemija mogu se javiti u razli&#x010D;itim rasponima te uzrokovati brojne komplikacije koje pak mogu imati u&#x010D;inke razli&#x010D;itog intenziteta kod razli&#x010D;itih bolesnika. (<xref ref-type="bibr" rid="r22"><italic>22</italic></xref>, <xref ref-type="bibr" rid="r23"><italic>23</italic></xref>)</p>
</sec>
<sec sec-type="other2">
<title>Klini&#x010D;ke komplikacije <italic>refeeding</italic>-sindroma</title>
<p>Klini&#x010D;ki simptomi <italic>refeeding</italic>-sindroma su razli&#x010D;iti i &#x010D;esto nepredvidivi te se mogu javiti akutno ili u kasnijoj fazi, a uklju&#x010D;uju uglavnom kardiovaskularne i neurolo&#x0161;ke poreme&#x0107;aje iako se mogu dugoro&#x010D;no odraziti na sve organske sustave (<xref ref-type="fig" rid="f3">Figure 3</xref>.). Promjene serumskih vrijednosti elektrolita mogu biti blage i asimptomatske, ali i ozbiljne te dovesti do komplikacija kao &#x0161;to su respiratorna i sr&#x010D;ana insuficijencija, aritmije, hipotenzija, delirij, koma i smrt. (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>) Nedostatak tiamina kao i nedostatak fosfata, kalija i magnezija utje&#x010D;e na sve organske sustave, a osobito na kardiovaskularni sustav te neurone i glia-stanice &#x017E;iv&#x010D;anog sustava. Najpoznatija bolest nedostatka tiamina jest bolest beriberi koja se dijeli na vla&#x017E;ni beriberi ili kardiomiopatiju s edemima i laktaktnom acidozom i suhi beriberi koji se odnosi na periferni neurolo&#x0161;ki nedostatak kod kojega Wernicke-Korsakoffljev sindrom nazivamo jo&#x0161; i mo&#x017E;danim beriberijem. (<xref ref-type="bibr" rid="r25"><italic>25</italic></xref>)</p>
<fig id="f3" position="float" fig-type="figure"><label>Figure 3</label><caption><p>Pathophysiology of RFS and clinical complications. Adapted from (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>): Boateng AA, Sriram K, Meguid MM, Crook M. Refeeding syndrome: treatment considerations based on collective analysis of literature case reports. Nutrition 2010;26(2):156-67. P, phosphorus; K, potassium; Mg, magnesium; Ca, calcium; ATP, adenosine triphosphate (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>)&#x2002;Poznata dugotrajna zlouporaba alkohola ili droga te inicijalno niske serumske vrijednosti elektolita dodatni su &#x010D;imbenici rizika za RFS/ Long-term alcohol or drug abuse and initially low serum electrolyte levels are additional risk factors for RFS; (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)&#x2002;restrikcija unosa natrija odnosi se prije svega na visoki i vrlo visoki rizik RFS-a tijekom prvih 5&#x2013;6 dana uvo&#x0111;enja nutritivne potpore/ restriction of sodium intake refers primarily to the high and very high risk of RFS during the first 5&#x2013;6 days of introducing nutritional support; (<xref ref-type="bibr" rid="r3"><italic>3</italic></xref>)&#x2002;profilakti&#x010D;ki unos tiamina nakon 3. dana kod srednjeg i visokog rizika RFS-a mo&#x017E;e se smanjiti na 100 mg dnevno te do 5. dana i potpuno ukinuti / prophylactic intake of thiamine in medium and high risk of RFS can be reduced to 100 mg per day after third day and after fifth day it can be completely discontinued; (<xref ref-type="bibr" rid="r4"><italic>4</italic></xref>)&#x2002;dnevna suplementacija mikronutrijenta, vitamina (200% PU) i mineralnih tvari (100% PU) / Recommended Dietary Allowance (RDA) of micronutrients, vitamins (200% RDA) and minerals (100% RDA).</p></caption><graphic xlink:href="LV-143-120-f3"></graphic></fig>
<p>Kardiovaskularne komplikacije. Malnutricija kao posljedica nedovoljnog unosa proteina i energije rezultira proporcionalnim gubitkom skeletnog i sr&#x010D;anog mi&#x0161;i&#x0107;ja (miokarda) koji utje&#x010D;e na sposobnost generiranja sr&#x010D;anoga minutnog volumena. Me&#x0111;utim, utjecaj malnutricije na atrofiju miokarda &#x010D;esto se ne prepoznaje na vrijeme uslijed kompenzacijskih mehanizama srca. Nadalje, smatra se da nedostatak tiamina dovodi do periferne vazodilatacije i zatajivanja srca s visokim udarnim volumenom te do smanjene proizvodnje energije koja uz nedostatak odre&#x0111;enih elektrolita utje&#x010D;e na smanjenje sr&#x010D;ane kontraktibilnosti. (<xref ref-type="bibr" rid="r26"><italic>26</italic></xref>) Kongestivno zatajenje srca rijetko nastaje u pothranjenih bolesnika, ali prilikom ponovnog uvo&#x0111;enja prehrane kod ovih bolesnika, osobito nakon duljeg razdoblja gladovanja, u&#x010D;estalost je visoka. Kardiomiopatija je opisana u literaturi kod bolesnika s anoreksijom nervozom, kroni&#x010D;nom zlouporabom alkohola te ozbiljnom pothranjenosti koja dalje pogor&#x0161;ava kardijalnu kaheksiju i atrofiju miokarda i time pove&#x0107;ava rizik sr&#x010D;anog zatajenja i sr&#x010D;anih aritmija. (<xref ref-type="bibr" rid="r27"><italic>27</italic></xref>, <xref ref-type="bibr" rid="r28"><italic>28</italic></xref>) Poja&#x010D;ano lu&#x010D;enje inzulina u ranim fazama ponovnog uvo&#x0111;enja prehrane u bolesnika u riziku RFS-a utje&#x010D;e na bubre&#x017E;nu retenciju natrija i vode uz posljedi&#x010D;no pove&#x0107;anje ekstracelularne teku&#x0107;ine, nastajanje edema, ali i ozbiljnijih komplikacija kao &#x0161;to su aritmije, kongestivno zatajenje srca i plu&#x0107;ni edem. (<xref ref-type="bibr" rid="r29"><italic>29</italic></xref>) Prekomjerni unos kristaloidnih otopina bogatih natrijem koje se &#x010D;esto primjenjuju kod hospitaliziranih bolesnika dodatno mo&#x017E;e pogor&#x0161;avati klini&#x010D;ku sliku. Osim toga, poreme&#x0107;aji elektrolita, osobito kalija, magnezija i fosfata koji se doga&#x0111;aju tijekom <italic>refeeding</italic> sindroma mogu dovesti i do ozbiljnih aritmija, ali istovremeno i do mnogih drugih komplikacija koje osim kardiovaskularnog i &#x017E;iv&#x010D;anog sustava zahva&#x0107;aju i druge organske sustave (respiratorni, gastrointestinalni, hematolo&#x0161;ki, urinarni, endokrinolo&#x0161;ki i neuromuskularni). Ozbiljna hipofosfatemija mo&#x017E;e dovesti do parestezije, gr&#x010D;eva, konvulzija, o&#x0161;te&#x0107;enja mi&#x0161;i&#x0107;ne funkcije, rabdomiolize, trombocitopenije, koagulopatije, respiratorne insuficijencije i imunosupresije. Ozbiljna hipomagnezemija i hipokalijemija mogu izazvati aritmije, sr&#x010D;anu insuficijenciju i arest, rabdomiolizu, respiratornu insuficijenciju i dr. (<xref ref-type="bibr" rid="r30"><italic>30</italic></xref>)</p>
<p>Neurolo&#x0161;ke komplikacije. Neurolo&#x0161;ke komplikacije <italic>refeeding</italic>-sindroma, od kojih je Wernickeova encefalopatija naj&#x010D;e&#x0161;&#x0107;a, poglavito se ve&#x017E;u uz nedostatak tiamina kod pothranjenih bolesnika nakon dugotrajne zlouporabe alkohola, ali su iste opisane i kod onkolo&#x0161;kih bolesnika, (<xref ref-type="bibr" rid="r31"><italic>31</italic></xref>) nakon gastrointestinalne kirurgije (<xref ref-type="bibr" rid="r32"><italic>32</italic></xref>, <xref ref-type="bibr" rid="r33"><italic>33</italic></xref>) te drugih klini&#x010D;kih stanja i bolesti. (<xref ref-type="bibr" rid="r34"><italic>34</italic></xref>) Prema studijama na &#x017E;ivotinjama te kod bolesnika s Wernickeovom encefalopatijom, smanjenje aktivnosti &#x03B1;-ketoglutarat dehidrogenaze u astrocitima najranija je biokemijska promjena koja se doga&#x0111;a pri nedostatku tiamina, koja dovodi do ranog o&#x0161;te&#x0107;enja glia-stanica, ali ne i neurona. Nakon 7 dana dolazi i do smanjene aktivnosti transketolaze, dok se aktivnost piruvat dehidrogenaze mijenja tek nakon 10 dana. (<xref ref-type="bibr" rid="r35"><italic>35</italic></xref>) Biokemijski gledano, kroz metaboli&#x010D;ke puteve ovisne o tiaminu, zbog nedostatka tiamina smanjena je aktivnost piruvat dehidrogenaze, nastaje manje acetil-CoA, piruvat prelazi u laktat koji se nakuplja u o&#x0161;te&#x0107;enom tkivu i utje&#x010D;e na nastanak metaboli&#x010D;ke acidoze. (<xref ref-type="bibr" rid="r36"><italic>36</italic></xref>) Nadalje, smanjena aktivnost piruvat dehidrogenaze i &#x03B1;-ketoglutarat dehidrogenaze dovodi do smanjene proizvodnje ATP-a u mozgu, inhibicije aktivnosti katehol-O-metil transferaze, a time pove&#x0107;anja razine neurotransmitera dopamina, koji mo&#x017E;e dovesti do delirija, halucinacija i iluzija. Pove&#x0107;anje &#x03B1;-ketoglutarata, prekursora glutamina, zbog hipoaktivnosti &#x03B1;-ketoglutarat dehidrogenaze, dovodi do ekscitacije i delirija, ali i osloba&#x0111;anja slobodnih radikala i neurotoksi&#x010D;nosti, &#x0161;to sve zajedno pridonosi propadanju neurona i glia-stanica te atrofiji CNS-a. (<xref ref-type="bibr" rid="r37"><italic>37</italic></xref>) Smanjena sinteza acetil-CoA dovodi do manjka acetilkolina, dok smanjena aktivnost &#x03B1;-ketoglutarat dehidrogenaze mo&#x017E;e dovesti do smanjene sinteze ostalih neurotransmitera (glutamata, gama-aminomasla&#x010D;ne kiseline i aspartata), time inhibiraju&#x0107;i sposobnost neurona da provode signal. (<xref ref-type="bibr" rid="r36"><italic>36</italic></xref>) Smanjena aktivnost transketolaze dovodi i do smanjene sinteze mijelina te poreme&#x0107;aja sinteze ribonukleinske kiseline, budu&#x0107;i da se smanjuje i proizvodnja riboze koja se koristi u sintezi nukleotida, nukleinskih kiselina, koenzima i polisaharida. (<xref ref-type="bibr" rid="r38"><italic>38</italic></xref>) Nadalje, smanjena aktivnost transketolaza utjecat &#x0107;e na pogor&#x0161;anje oksidativnog stresa uslijed smanjene proizvodnje reduciranog NADPH-a u pentoza fosfatnom putu, molekule koja ima va&#x017E;nu ulogu u za&#x0161;titi stanica od kisikovih radikala (stvaranje reduciranog glutationa) te kao reducens u biosintetskim reakcijama (lipida, kolesterola, neurotransmitera). (<xref ref-type="bibr" rid="r39"><italic>39</italic></xref>) Va&#x017E;no je napomenuti da je i magnezij uz tiamin kofaktor transketolazama te nedostatak magnezija koji je &#x010D;esto prisutan kod RFS-a smanjuje njihovu enzimsku aktivnost. (<xref ref-type="bibr" rid="r40"><italic>40</italic></xref>) Kod bolesnika s kroni&#x010D;nom zlouporabom alkohola dolazi do o&#x0161;te&#x0107;enja CNS-a, zbog pove&#x0107;anja aktivnosti enzima koji proizvode reaktivne radikale kisika (engl. <italic>reactive oxygen species</italic> &#x2013; <italic>ROS</italic>) te pove&#x0107;anja nastanka acetaldehida (metabolita etanola) koji dalje pridonosi nastanku ROS-a, pove&#x0107;anju oksidativnog stresa i neurodegeneraciji. (<xref ref-type="bibr" rid="r41"><italic>41</italic></xref>) Iako se kroni&#x010D;na uporaba alkohola povezuje s WE, ona ne&#x0107;e nastati ukoliko je tiamin dovoljno zastupljen u prehrani. Ono &#x0161;to doprinosi nastanku WE kod alkoholi&#x010D;ara prije svega je nedovoljan unos putem hrane, malnutricija, pove&#x0107;ana potreba za tiaminom uslijed metabolizma alkohola, smanjeni transport tiamina kroz crijevnu sluznicu, o&#x0161;te&#x0107;enje jetre i njezine sposobnosti za pohranjivanje vitamina te pretvorbe u tiamin pirofosfat. (<xref ref-type="bibr" rid="r42"><italic>42</italic></xref>) Rano otkrivanje nedostatka tiamina obi&#x010D;no je ote&#x017E;ano s obzirom na to da su klini&#x010D;ki simptomi kao umor, glavobolja i razdra&#x017E;ljivost blagi i nespecifi&#x010D;ni. WE karakterizira nagli nastanak mentalnih i motori&#x010D;kih poreme&#x0107;aja, smetenosti, nistagmusa, djelomi&#x010D;ne oftalmoplegije i ataksije, te ako se ne prepozna i ne lije&#x010D;i mo&#x017E;e dovesti i do smrtnog ishoda. Kasna komplikacija Wernickeove encefalopatije zove se Korsakoffljeva psihoza ili Wernicke-Korsakoffljev sindrom, koji se razvija u 80% bolesnika s nelije&#x010D;enom WE, (<xref ref-type="bibr" rid="r43"><italic>43</italic></xref>) a karakterizira ga gubitak pam&#x0107;enja, smetenost i promjene u pona&#x0161;anju. Zapravo se radi o dva neurolo&#x0161;ka stanja koja se odvijaju istodobno i koja imaju visoki morbiditet i mortalitet kod bolesnika sa zlouporabom alkohola. (<xref ref-type="bibr" rid="r44"><italic>44</italic></xref>)</p>
<p>Laktatna acidoza. Kod nedostatka tiamina piruvat se ne mo&#x017E;e pretvoriti u acetil-CoA te se putem enzima laktat dehidrogenaze reducira u laktat. Tijekom tog procesa dolazi i do osloba&#x0111;anja protona (vodikovih iona) u jednakom broju s molekulama proizvedenog laktata, &#x0161;to dovodi do metaboli&#x010D;ke acidoze. Sekundarno nastaje i hiperglikemija, jer se vi&#x0161;ak laktata u jetri metabolizira u glukozu putem glukoneogeneze, a nedostatak tiamina koji je va&#x017E;an za endokrine i egzokrine funkcije pankreasa mo&#x017E;e uzrokovati pogor&#x0161;anje sekrecije i sinteze inzulina. (<xref ref-type="bibr" rid="r45"><italic>45</italic></xref>)</p>
</sec>
<sec sec-type="other3">
<title>Prevencija i lije&#x010D;enje <italic>refeeding</italic>-sindroma</title>
<p>Prepoznavanje bolesnika koji su u riziku, usko pra&#x0107;enje bolesnika i odgovaraju&#x0107;a nutritivna intervencija klju&#x010D; su prevencije nastanka RFS-a. Prema razli&#x010D;itim prikazima slu&#x010D;ajeva i preglednim radovima glavni &#x010D;imbenici rizika za nastanak RFS-a su indeks tjelesne mase (ITM) &lt;16 kg/m<sup>2</sup>, nenamjeran gubitak na tjelesnoj masi &gt;15% u 3 do 6 mjeseci, minimalan ili nedovoljan peroralni unos hrane dulji od 10 dana te niske serumske koncentracije kalija, fosfata ili magnezija prije uvo&#x0111;enja nutritivne potpore. (<xref ref-type="bibr" rid="r46"><italic>46</italic></xref>) Kod rizi&#x010D;nih bolesnika, prije svega, va&#x017E;no je izbje&#x0107;i prekomjeran kalorijski unos, osobito same glukoze. <italic>Refeeding</italic>-sindrom se mo&#x017E;e izbje&#x0107;i postupnim uvo&#x0111;enjem nutritivne potpore kroz nekoliko dana uz nadomjesnu primjenu tiamina i elektrolita sukladno serumskim vrijednostima. U literaturi postoji niz preglednih radova temeljenih na razli&#x010D;itim prikazima slu&#x010D;ajeva, smjernicama te ekspertnim mi&#x0161;ljenjima vezanim uz preporuke prevencije RFS-a. (<xref ref-type="bibr" rid="r21"><italic>21</italic></xref>&#x2013;<xref ref-type="bibr" rid="r23"><italic>23</italic></xref>, <xref ref-type="bibr" rid="r47"><italic>47</italic></xref>)</p>
<p>Kod bolesnika s procijenjenim rizikom nastanka RFS-a nutritivna potpora, bilo da se radi o peroralnom, enteralnom ili parenteralnom hranjenju, uvodi se kroz nekoliko dana s inicijalnim unosom od oko 30&#x2013;50% ukupnih potreba u prva 3 dana ovisno o stupnju rizika, a zatim se isti postupno pove&#x0107;ava (<xref ref-type="fig" rid="f4">Figure 4</xref>.). Kod izrazito vulnerabilnih bolesnika vrlo visokog rizika za RFS kalorijski unos zapo&#x010D;inje se sa samo 5&#x2013;10 kcal/kg/dan uz dnevno pra&#x0107;enje serumskih vrijednosti elektrolita te supstituciju istih prema potrebi. Tiamin je nezaobilazan dio prevencije RFS-a te se uobi&#x010D;ajeno kroz 5&#x2013;7 dana primjenjuje u profilakti&#x010D;kim dozama od 100&#x2013;300 mg 30 minuta prije hranjenja. (<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>) Osim kalorijskog unosa va&#x017E;no je izbje&#x0107;i i prekomjeran unos teku&#x0107;ine i natrija, osobito u ranim fazama uvo&#x0111;enja nutritivne potpore, kako bi se prevenirale gore navedene komplikacije vezane uz retenciju natrija i ekspanziju ekstracelularne teku&#x0107;ine. Hospitalizirani bolesnici nerijetko primaju kristaloidne otopine koje obi&#x010D;no sadr&#x017E;e visok udio natrija te je kod procijenjenog vrlo visokog i visokog rizika nastanka RFS-a potrebno ograni&#x010D;iti unos natrija te izbje&#x0107;i prekomjerni intravenozni unos teku&#x0107;ina putem ovih otopina i/ili lijekova. Porast na tjelesnoj masi ve&#x0107;i od 1 kg tjedno mogao bi upu&#x0107;ivati na retenciju vode i natrija. Kod bolesnika s rizikom RFS-a (kao i kod onih kod kojih je nastao RFS), potrebno je prvih nekoliko dana intenzivno pratiti vitalne znakove (EKG, otkucaje srca, krvni tlak, brzinu disanja), zatim mentalni status i neurolo&#x0161;ke funkcije, laboratorijske parametre, osobito elektrolite, ravnote&#x017E;u teku&#x0107;ina i znakove edema. (<xref ref-type="bibr" rid="r48"><italic>48</italic></xref>)</p>
<fig id="f4" position="float" fig-type="figure"><label>Figure 4</label><caption><p>Algorithm for prevention of refeeding syndrome. Adapted according to (<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>): Friedli N, Stanga Z, Culkin A et al. Management and prevention of refeeding syndrome in medical inpatients: An evidence-based and consensus-supported algorithm. Nutrition 2018;47:13&#x2013;20.</p></caption><graphic xlink:href="LV-143-120-f4"></graphic></fig>
<p>Lije&#x010D;enje <italic>refeeding</italic>-sindroma ovisit &#x0107;e o stupnju istoga i prisutnim komplikacijama, a uklju&#x010D;uje nadoknadu elektrolita i tiamina, korekciju ravnote&#x017E;e vode i natrija, kalorijskog unosa te dodatnu suplementaciju mikronutrijenata. Sni&#x017E;enje serumskih vrijednosti fosfata ispod 0,6 mmol/L ili bilo koja dva elektrolita (kalij, fosfati, magnezij) ispod referentnih vrijednosti kod bolesnika u riziku sumnja je na RFS, a ukoliko bolesnik ima prisutne i klini&#x010D;ke znakove poput edema, tahikardije ili tahipneje, mo&#x017E;emo re&#x0107;i da je bolesnik razvio RFS. (<xref ref-type="bibr" rid="r47"><italic>47</italic></xref>) Nadoknada elektrolita ovisi o serumskim vrijednostima, tjelesnoj masi bolesnika te kalorijskom unosu, a odvija se tijekom hranjenja koje se mo&#x017E;e smanjiti ukoliko se radi o prekomjernom kalorijskom unosu, ali se ne prekida u potpunosti. Kod blagog do umjerenog sni&#x017E;enja serumskih vrijednosti elektrolita, ako bolesnik nema simptoma, nadoknada je mogu&#x0107;a i peroralnim putem uz dnevno pra&#x0107;enje istih, dok je kod ozbiljnog potrebna intravenska nadoknada uz kontrolu serumskih vrijednosti svakih 8&#x2013;12 h. Kod ozbiljne hipofosfatemije fosfati se obi&#x010D;no primjenjuju kao kalijeva (kalij hidrogen fosfat i kalij dihidrogen fosfat) ili natrijeva sol, odnosno otopina monobazne i dibazne soli kalija ili natrija koje je potrebno neposredno prije primjene razrijediti u 5-postotnoj glukozi ili fiziolo&#x0161;koj otopini (<xref ref-type="table" rid="t1">Table 1</xref>.). Upravo zbog toga potrebno je uzeti u obzir i dodatni unos natrija i kalija putem ove soli. Tijekom intravenozne supstitucije fosfata potrebno je redovito kontrolirati serumske vrijednosti i ostalih elektrolita, osobito kalcija, kako bi se izbjegle komplikacije hipokalcijemije.</p>
<table-wrap id="t1" position="float">
<label>Table 1</label><caption><title>Recommendation of phosphate substitution in RFS hypophosphatemia (<xref ref-type="bibr" rid="r24"><italic>24</italic></xref>, <xref ref-type="bibr" rid="r48"><italic>48</italic></xref>)</title>
</caption>
<table frame="hsides" rules="groups">
<col width="35.51%"/>
<col width="21.49%"/>
<col width="21.5%"/>
<col width="21.5%"/>
<thead>
<tr>
<th valign="middle" align="left" scope="col" style="border-left: solid 0.75pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Hipofosfatemija / Hypophosphatemia</th>
<th valign="middle" colspan="3" align="left" scope="colgroup" style="border-left: solid 0.50pt; border-top: solid 0.75pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Nadoknada / Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Blaga (0,8 &#x2013; 0,6 mmol/L) / Mild (0.8 &#x2013; 0.6 mmol/L)</td>
<td valign="middle" colspan="3" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">Peroralno: tablete/efervete natrijevog fosfata (16 mmol fosfata 1 &#x2013; 2 x dnevno) / Oral supplementation: sodium phosphate (16 mmol phosphate QD to BID)</td>
</tr>
<tr>
<td valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Umjerena (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) (0,6&#x2013;0,4 mmol/L) i ozbiljna (&lt;0,4 mmol/L) / Moderate (<xref ref-type="bibr" rid="r1"><italic>1</italic></xref>) (0.6&#x2013;0.4 mmol/L) and severe (&lt;0.4 mmol/L)</td>
<td valign="middle" colspan="3" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">IV kalijev ili natrijev fosfat 0,3 &#x2013; 0,6 mmol/kg/dan (<xref ref-type="bibr" rid="r2"><italic>2</italic></xref>)<break/>/ IV potassium or sodium phosphate 0.3 &#x2013; 0.6 mmol/kg/day<sup>2</sup><break/>Maks. koncentracija za perifernu venu do 15 mmol fosfata u 500 ml 5% glukoze ili 0,9% NaCl / brzina infuzije 4&#x2013;6 h / Max. concentration for peripheral vein up to 15 mmol of phosphate in 500 ml 5% glucose or 0.9% NaCl / infusion rate 4&#x2013;6 h</td>
</tr>
<tr>
<td rowspan="2" valign="middle" align="left" style="border-left: solid 0.75pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt" scope="row">Ukupno / Total</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">TM &lt; 50 kg</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.50pt">TM 50 &#x2013; 70 kg</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.50pt">TM &gt; 70 kg</td>
</tr>
<tr>
<td valign="middle" colspan="1" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt" scope="row">IV: 10&#x2013;30 mmol</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.50pt; border-bottom: solid 0.75pt">IV: 20&#x2013;40 mmol</td>
<td valign="middle" align="left" style="border-left: solid 0.50pt; border-top: solid 0.50pt; border-right: solid 0.75pt; border-bottom: solid 0.75pt">IV: 30&#x2013;50 mmol</td>
</tr>
</tbody>
</table><table-wrap-foot>
<p>QD &#x2013; quaque die (once a day); BID &#x2013; bis in die (twice a day); IV-intravenozno / intravenously; TM / BW &#x2013; tjelesna masa / body weight.</p>
<p><sup>1</sup> Kod umjerene hipofosfatemije, nadoknada fosfata mogu&#x0107;a je i peroralnim putem kao kod blage hipofosfatemije, me&#x0111;utim, ukoliko bolesnik ima simptome ili nuspojave kao primjerice proljev na peroralni oblik fosfata, potrebno je supstituirati fosfate IV. / In moderate hypophosphatemia, phosphate replacement is also possible orally as in mild hypophosphatemia, however, if the patient has symptoms or side effects such as diarrhea on the oral phosphate form, phosphates IV should be substituted.</p>
<p><sup>2</sup> Kod bubre&#x017E;ne isuficijencije potrebno je korigirati dozu (&lt;50% inicijalne doze). Kod bolesnika u JIL-u koncentracija fosfata u otopini kao i doziranje mogu biti druga&#x010D;iji. / Dose adjustment (&lt;50% of initial dose) should be corrected for renal insufficiency. In ICU patients the phosphate concentration in the solution as well as the dosage may be different.</p>
</table-wrap-foot></table-wrap>
<p>Umjerena i ozbiljna hipomagnezemija kod RFS-a lije&#x010D;i se intravenozno s razrije&#x0111;enom otopinom magnezijeva sulfata (kod magnezija u serumu &lt;0,5 mmol/L, 4&#x2013;6 g MgSO<sub>4</sub> ili 0,2 mmol/kg/dan intravenozno ili 0,4 mmol/kg/dan oralno). S obzirom na to da se magnezij sporo distribuira izme&#x0111;u ekstracelularne i intracelularne teku&#x0107;ine, a vrlo brzo eliminira putem bubrega, kod stanja koja nisu hitna preporu&#x010D;uje se duljina infuzije magnezij sulfata od 6&#x2013;12 h. (<xref ref-type="bibr" rid="r49"><italic>49</italic></xref>) Korekcija hipokalijemije bilo koje etiologije op&#x0107;enito je dobro poznata lije&#x010D;nicima, a kod RFS-a ista se korigira IV putem kalijeva klorida koji se inicijalno, ovisno o stupnju hipokalijemije, daje od 20&#x2013;40 mmol, zatim se doziranje ponavlja ukoliko nakon 6&#x2013;8 h serumske vrijednosti nisu u referetnom rasponu (dnevni unos 1&#x2013;2 mmol/kg/dan kalija ovisno o serumskim vrijednostima, oralno ili intravenozno). Hipokalijemija se mo&#x017E;e pogor&#x0161;ati u slu&#x010D;aju prisutne hipomagnezemije, jer je magnezij va&#x017E;an za aktivnost kalij-natrijeve pumpe, a time i za resorpciju kalija u tubulima, pa je potrebno istovremeno korigirati oba elektrolita. (<xref ref-type="bibr" rid="r49"><italic>49</italic></xref>) Kao i kod fosfata, potrebna je prilagodba doze ako bolesnik ima bubre&#x017E;nu insuficijenciju. Nadoknada &#x017E;eljeza nije preporu&#x010D;ljiva u prvih nekoliko dana uvo&#x0111;enja nutritivne potpore bolesnika u riziku budu&#x0107;i da ista mo&#x017E;e utjecati na pogor&#x0161;anje hipokalijemije te nastajanje i pogor&#x0161;anje hipofosfatemije. (<xref ref-type="bibr" rid="r50"><italic>50</italic></xref>) Kod bolesnika s neurolo&#x0161;kim simptomima koji upu&#x0107;uju na WE potrebno je odmah dati tiamin intravenskim putem, s obzirom na to da je peroralni oblik neu&#x010D;inkovit u lije&#x010D;enju WE. Ne postoji konsenzus oko optimalne doze i oblika pripreme tiamina te trajanja lije&#x010D;enja RFS-a ili WE, ve&#x0107; razli&#x010D;ite preporuke za primjenu istoga koje proizlaze iz znanstvenih publikacija. Prema smjernicama za dijagnostiku, lije&#x010D;enje i prevenciju WE Europske federacije neurolo&#x0161;kih dru&#x0161;tava, kod lije&#x010D;enja WE potrebno je dati visoke doze od 500 mg i.v. tri puta dnevno kroz nekoliko dana (zbog kratkog poluvijeka slobodnog tiamina u krvi od samo 96 minuta). (<xref ref-type="bibr" rid="r51"><italic>51</italic></xref>)</p>
</sec>
<sec sec-type="other4">
<title>Zaklju&#x010D;ak</title>
<p>Prepoznavanje i intenzivno pra&#x0107;enje rizi&#x010D;nih bolesnika uz adekvatnu nutritivnu potporu i profilakti&#x010D;ku primjenu tiamina te razumijevanje patofiziologije i komplikacija RFS-a va&#x017E;no je za prevenciju nastanka, ali i pravovremeno i adekvatno lije&#x010D;enje istoga. Iako je do sada u znanstvenoj literaturi objavljen velik broj prikaza slu&#x010D;ajeva i preglednih radova vezanih uz RFS, u&#x010D;estalost RFS-a jo&#x0161; uvijek je visoka. U modernim i razvijenim bolni&#x010D;kim sustavima ovim se problemom bave multidisciplinarni nutritivni timovi koje &#x010D;ine lije&#x010D;nici, medicinske sestre, farmaceuti i nutricionisti sa znanjem i ekspertizom na podru&#x010D;ju klini&#x010D;ke prehrane. Takvi timovi imaju va&#x017E;nu ulogu u prevenciji i lije&#x010D;enju <italic>refeeding</italic>-sindroma, ali i edukaciji ostalih zdravstvenih djelatnika.</p>
</sec>
</body>
<back>
<ref-list>
<title>Literatura</title>
<ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehanna</surname><given-names>HM</given-names></name><name><surname>Moledina</surname><given-names>J</given-names></name><name><surname>Travis</surname><given-names>J</given-names></name></person-group>. <article-title>Refeeding syndrome: what it is, and how to prevent and treat it.</article-title> <source>BMJ</source>. <year>2008</year>;<volume>336</volume>(<issue>7659</issue>):<fpage>1495</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.a301</pub-id><pub-id pub-id-type="pmid">18583681</pub-id></mixed-citation></ref>
<ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitker</surname><given-names>MA</given-names></name><name><surname>Mattman</surname><given-names>PE</given-names></name><name><surname>Bliss</surname><given-names>TL</given-names></name></person-group>. <article-title>A clinical study of malnutrition in Japanese prisoners of war.</article-title> <source>Ann Intern Med</source>. <year>1951</year>;<volume>35</volume>:<fpage>69</fpage>&#x2013;<lpage>96</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-35-1-69</pub-id><pub-id pub-id-type="pmid">14847450</pub-id></mixed-citation></ref>
<ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campos-Ferrer</surname><given-names>C</given-names></name><name><surname>Cervera-Montes</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>A</given-names></name><name><surname>Borr&#x00E1;s</surname><given-names>S</given-names></name><name><surname>G&#x00F3;mez</surname><given-names>E</given-names></name><name><surname>Ricart</surname><given-names>C</given-names></name></person-group>. <article-title>Cardiogenic shock associated with inappropriate nutritional regimen: refeeding syndrome.</article-title> <source>Nutr Hosp</source>. <year>2004</year>;<volume>19</volume>(<issue>3</issue>):<fpage>175</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">15211727</pub-id></mixed-citation></ref>
<ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crook</surname><given-names>MA</given-names></name><name><surname>Panteli</surname><given-names>JV</given-names></name></person-group>. <article-title>The refeeding syndrome and hypophosphataemia in the elderly.</article-title> <source>J Intern Med</source>. <year>2005</year>;<volume>257</volume>:<fpage>397</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2796.2005.01492.x</pub-id><pub-id pub-id-type="pmid">15836655</pub-id></mixed-citation></ref>
<ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rio</surname><given-names>A</given-names></name><name><surname>Whelan</surname><given-names>K</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Reidlinger</surname><given-names>DP</given-names></name><name><surname>Smeeton</surname><given-names>N</given-names></name></person-group>. <article-title>Occurrence of refeeding syndrome in adults started on artificial nutrition support: prospective cohort study.</article-title> <source>BMJ Open</source>. <year>2013</year>;<volume>3</volume>:<elocation-id>e002173</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2012-002173</pub-id><pub-id pub-id-type="pmid">23315514</pub-id></mixed-citation></ref>
<ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duca</surname><given-names>J</given-names></name><name><surname>Lum</surname><given-names>CJ</given-names></name><name><surname>Lo</surname><given-names>AM</given-names></name></person-group>. <article-title>Elevated Lactate Secondary to Gastrointestinal Beriberi.</article-title> <source>J Gen Intern Med</source>. <year>2016</year>;<volume>31</volume>(<issue>1</issue>):<fpage>133</fpage>&#x2013;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s11606-015-3326-2</pub-id><pub-id pub-id-type="pmid">25876741</pub-id></mixed-citation></ref>
<ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camp</surname><given-names>MA</given-names></name><name><surname>Allon</surname><given-names>M</given-names></name></person-group>. <article-title>Severe hypophosphatemia in hospitalized patients.</article-title> <source>Miner Electrolyte Metab</source>. <year>1990</year>;<volume>16</volume>:<fpage>365</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">2089250</pub-id></mixed-citation></ref>
<ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marik</surname><given-names>PE</given-names></name><name><surname>Bedigian</surname><given-names>MK</given-names></name></person-group>. <article-title>Refeeding Hypophosphatemia in Critically Ill Patients in an Intensive Care Unit.</article-title> <source>Arch Surg</source>. <year>1996</year>;<volume>131</volume>:<fpage>1043</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1001/archsurg.1996.01430220037007</pub-id><pub-id pub-id-type="pmid">8857900</pub-id></mixed-citation></ref>
<ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraaijenbrink</surname><given-names>BV</given-names></name><name><surname>Lambers</surname><given-names>WM</given-names></name><name><surname>Mathus-Vliegen</surname><given-names>EM</given-names></name><name><surname>Siegert</surname><given-names>CE</given-names></name></person-group>. <article-title>Incidence of refeeding syndrome in internal medicine patients.</article-title> <source>Neth J Med</source>. <year>2016</year>;<volume>74</volume>:<fpage>116</fpage>&#x2013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">27020991</pub-id></mixed-citation></ref>
<ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeki</surname><given-names>S</given-names></name><name><surname>Culkin</surname><given-names>A</given-names></name><name><surname>Gabe</surname><given-names>SM</given-names></name><name><surname>Nightingale</surname><given-names>JM</given-names></name></person-group>. <article-title>Refeeding hypophosphataemia is more common in enteral than parenteral feeding in adult in patients.</article-title> <source>Clin Nutr</source>. <year>2011</year>;<volume>30</volume>(<issue>3</issue>):<fpage>365</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.clnu.2010.12.001</pub-id><pub-id pub-id-type="pmid">21256638</pub-id></mixed-citation></ref>
<ref id="r11"><label>11</label><mixed-citation publication-type="book">National Institute for Health and Care Excellence. Clinical guidelines. London: National Institute for Health and Care Excellence; 2003.</mixed-citation></ref>
<ref id="r12"><label>12</label><mixed-citation publication-type="book">Biokemija SL. Zagreb: &#x0160;kolska knjiga; 1991.</mixed-citation></ref>
<ref id="r13"><label>13</label><mixed-citation publication-type="book">Pelley JW. Integration of Carbohydrate, Fat, and Amino Acid Metabolism. Elsevier&#x2019;s Integrated Review Biochemistry. 2. izd. Philadelphia: Elsevier Saunders; 2012, str. 109&#x2013;19.</mixed-citation></ref>
<ref id="r14"><label>14</label><mixed-citation publication-type="book">Berg JM, Tymoczko JL, Stryer L. Biochemistry. 5. izd. New York: WH Freeman; 2002.</mixed-citation></ref>
<ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen</surname><given-names>BCP</given-names></name><name><surname>Donath</surname><given-names>WF</given-names></name></person-group>. <article-title>Antineuritische vitamine.</article-title> <source>Chem Weekbl</source>. <year>1926</year>;<volume>23</volume>:<fpage>1387</fpage>.</mixed-citation></ref>
<ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonsdale</surname><given-names>D</given-names></name></person-group>. <article-title>A review of the biochemistry, metabolism and clinical benefits of thiamin(e) and its derivatives.</article-title> <source>Evid Based Complement Alternat Med</source>. <year>2006</year>;<volume>3</volume>(<issue>1</issue>):<fpage>49</fpage>&#x2013;<lpage>59</lpage>. <pub-id pub-id-type="doi">10.1093/ecam/nek009</pub-id><pub-id pub-id-type="pmid">16550223</pub-id></mixed-citation></ref>
<ref id="r17"><label>17</label><mixed-citation publication-type="book">Institute of Medicine. Food and Nutrition Board. Dietary Reference Intakes: Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington: National Academies Press; 1998.</mixed-citation></ref>
<ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Depeint</surname><given-names>F</given-names></name><name><surname>Bruce</surname><given-names>WR</given-names></name><name><surname>Shangari</surname><given-names>N</given-names></name><name><surname>Mehta</surname><given-names>R</given-names></name><name><surname>O&#x2019;Brien</surname><given-names>PJ</given-names></name></person-group>. <article-title>Mitochondrial function and toxicity: role of the B vitamin family on mitochondrial energy metabolism.</article-title> <source>Chem Biol Interact</source>. <year>2006</year>;<volume>163</volume>(<issue>1&#x2013;2</issue>):<fpage>94</fpage>&#x2013;<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.cbi.2006.04.014</pub-id><pub-id pub-id-type="pmid">16765926</pub-id></mixed-citation></ref>
<ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossouw</surname><given-names>JE</given-names></name><name><surname>Labadarios</surname><given-names>D</given-names></name><name><surname>Krasner</surname><given-names>N</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name></person-group>. <article-title>Red blood cell transketolase activity and the effect of thiamine supplementation in patients with chronic liver disease.</article-title> <source>Scand J Gastroenterol</source>. <year>1978</year>;<volume>13</volume>(<issue>2</issue>):<fpage>133</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3109/00365527809181738</pub-id><pub-id pub-id-type="pmid">635453</pub-id></mixed-citation></ref>
<ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bettendorff</surname><given-names>L</given-names></name></person-group>. <article-title>Thiamine in excitable tissues: reflections on a non-cofactor role.</article-title> <source>Metab Brain Dis</source>. <year>1994</year>;<volume>9</volume>:<fpage>183</fpage>&#x2013;<lpage>209</lpage>. <pub-id pub-id-type="doi">10.1007/BF01991194</pub-id><pub-id pub-id-type="pmid">7838063</pub-id></mixed-citation></ref>
<ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>LU</given-names></name><name><surname>Ahmed</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><name><surname>Macfie</surname><given-names>J</given-names></name></person-group>. <article-title>Refeeding syndrome: a literature review.</article-title> <source>Gastroenterol Res Pract</source>. <year>2011</year>;<volume>2011</volume>:<fpage>19</fpage>&#x2013;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1155/2011/410971</pub-id><pub-id pub-id-type="pmid">20886063</pub-id></mixed-citation></ref>
<ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stanga</surname><given-names>Z</given-names></name><name><surname>Brunner</surname><given-names>A</given-names></name><name><surname>Leuenberger</surname><given-names>M</given-names></name><etal/></person-group> <article-title>Nutrition in clinical practice&#x2014;the refeeding syndrome: illustrative cases and guidelines for prevention and treatment.</article-title> <source>Eur J Clin Nutr</source>. <year>2008</year>;<volume>62</volume>(<issue>6</issue>):<fpage>687</fpage>&#x2013;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ejcn.1602854</pub-id><pub-id pub-id-type="pmid">17700652</pub-id></mixed-citation></ref>
<ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehanna</surname><given-names>H</given-names></name><name><surname>Nankivell</surname><given-names>PC</given-names></name><name><surname>Moledina</surname><given-names>J</given-names></name><name><surname>Travis</surname><given-names>J</given-names></name></person-group>. <article-title>Refeeding syndrome &#x2013; awareness, prevention and management.</article-title> <source>Head Neck Oncol</source>. <year>2009</year>;<volume>1</volume>(<issue>1</issue>):<fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/1758-3284-1-4</pub-id><pub-id pub-id-type="pmid">19284691</pub-id></mixed-citation></ref>
<ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boateng</surname><given-names>AA</given-names></name><name><surname>Sriram</surname><given-names>K</given-names></name><name><surname>Meguid</surname><given-names>MM</given-names></name><name><surname>Crook</surname><given-names>M</given-names></name></person-group>. <article-title>Refeeding syndrome: treatment considerations based on collective analysis of literature case reports.</article-title> <source>Nutrition</source>. <year>2010</year>;<volume>26</volume>(<issue>2</issue>):<fpage>156</fpage>&#x2013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2009.11.017</pub-id><pub-id pub-id-type="pmid">20122539</pub-id></mixed-citation></ref>
<ref id="r25"><label>25</label><mixed-citation publication-type="web">MSD priru&#x010D;nik dijagnostike i terapije. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.msd-prirucnici.placebo.hr/msd-prirucnik/poremecaji-prehrane/manjak-vitamina-ovisnost-o-njima-i-toksicnost/tiamin">http://www.msd-prirucnici.placebo.hr/msd-prirucnik/poremecaji-prehrane/manjak-vitamina-ovisnost-o-njima-i-toksicnost/tiamin</ext-link>. Pristupljeno 21. 7. 2020.</mixed-citation></ref>
<ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>JG</given-names></name><name><surname>Kiess</surname><given-names>MC</given-names></name><name><surname>Chan-Yan</surname><given-names>CC</given-names></name></person-group>. <article-title>Malnutrition and the heart.</article-title> <source>CMAJ</source>. <year>1986</year>;<volume>135</volume>(<issue>7</issue>):<fpage>753</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">3093042</pub-id></mixed-citation></ref>
<ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohn</surname><given-names>MR</given-names></name><name><surname>Golden</surname><given-names>NH</given-names></name><name><surname>Shenker</surname><given-names>IR</given-names></name></person-group>. <article-title>Cardiac arrest and delirium: presentations of the refeeding syndrome in severely malnourished adolescents with anorexia nervosa.</article-title> <source>J Adolesc Health</source>. <year>1998</year>;<volume>22</volume>(<issue>3</issue>):<fpage>239</fpage>&#x2013;<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1016/S1054-139X(97)00163-8</pub-id><pub-id pub-id-type="pmid">9502012</pub-id></mixed-citation></ref>
<ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RJH</given-names></name><name><surname>Chew</surname><given-names>D</given-names></name></person-group>. <article-title>Re-feeding syndrome and alcoholic cardiomyopathy: A case of interacting diagnoses.</article-title> <source>J Cardiol Cases</source>. <year>2016</year>;<volume>14</volume>(<issue>3</issue>):<fpage>90</fpage>&#x2013;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.jccase.2016.04.006</pub-id><pub-id pub-id-type="pmid">30546674</pub-id></mixed-citation></ref>
<ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veverbrants</surname><given-names>E</given-names></name><name><surname>Arky</surname><given-names>RA</given-names></name></person-group>. <article-title>Effects of fasting and refeeding: I. Studies on sodium, potassium and water excretion on a constant electrolyte and fluid intake.</article-title> <source>J Clin Endocrinol Metab</source>. <year>1969</year>;<volume>29</volume>:<fpage>55</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1210/jcem-29-1-55</pub-id><pub-id pub-id-type="pmid">5762322</pub-id></mixed-citation></ref>
<ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraft</surname><given-names>MD</given-names></name><name><surname>Btaiche</surname><given-names>IF</given-names></name><name><surname>Sacks</surname><given-names>GS</given-names></name></person-group>. <article-title>Review of the refeeding syndrome.</article-title> <source>Nutr Clin Pract</source>. <year>2005</year>;<volume>20</volume>(<issue>6</issue>):<fpage>625</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1177/0115426505020006625</pub-id><pub-id pub-id-type="pmid">16306300</pub-id></mixed-citation></ref>
<ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Isenberg-Grzeda</surname><given-names>E</given-names></name><name><surname>Alici</surname><given-names>Y</given-names></name><name><surname>Hatzoglou</surname><given-names>V</given-names></name><name><surname>Nelson</surname><given-names>C</given-names></name><name><surname>Breitbart</surname><given-names>W</given-names></name></person-group>. <article-title>Nonalcoholic Thiamine-Related Encephalopathy (Wernicke-Korsakoff Syndrome) Among Inpatients With Cancer: A Series of 18 Cases.</article-title> <source>Psychosomatics</source>. <year>2016</year>;<volume>57</volume>(<issue>1</issue>):<fpage>71</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.psym.2015.10.001</pub-id><pub-id pub-id-type="pmid">26791514</pub-id></mixed-citation></ref>
<ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rufa</surname><given-names>A</given-names></name><name><surname>Rosini</surname><given-names>F</given-names></name><name><surname>Cerase</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Wernicke Encephalopathy After Gastrointestinal Surgery for Cancer: Causes of Diagnostic Failure or Delay</article-title>. <source>Int J Neurosci</source>. <year>2011</year>;<volume>121</volume>(<issue>4</issue>):<fpage>201</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.3109/00207454.2010.544430</pub-id><pub-id pub-id-type="pmid">21244301</pub-id></mixed-citation></ref>
<ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krznaric</surname><given-names>Z</given-names></name><name><surname>Vranesic Bender</surname><given-names>D</given-names></name><name><surname>Ljubas Kelecic</surname><given-names>D</given-names></name><name><surname>Brinar</surname><given-names>M</given-names></name></person-group>. <article-title>Wernicke&#x2019;s encephalopathy during parenteral nutrition in a Crohn&#x2019;s disease patient.</article-title> <source>Nutrition</source>. <year>2011</year>;<volume>27</volume>(<issue>4</issue>):<fpage>503</fpage>&#x2013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2010.12.005</pub-id><pub-id pub-id-type="pmid">21392706</pub-id></mixed-citation></ref>
<ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Galvin</surname><given-names>R</given-names></name><name><surname>Br&#x00E5;then</surname><given-names>G</given-names></name><name><surname>Ivashynka</surname><given-names>A</given-names></name><name><surname>Hillbom</surname><given-names>M</given-names></name><name><surname>Tanasescu</surname><given-names>R</given-names></name><name><surname>Leone</surname><given-names>MA</given-names></name></person-group>. <article-title>EFNS guidelines for diagnosis, therapy and prevention of Wernicke encephalopathy.</article-title> <source>Eur J Neurol</source>. <year>2010</year>;<volume>17</volume>(<issue>12</issue>):<fpage>1408</fpage>&#x2013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1111/j.1468-1331.2010.03153.x</pub-id><pub-id pub-id-type="pmid">20642790</pub-id></mixed-citation></ref>
<ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sechi</surname><given-names>G</given-names></name><name><surname>Serra</surname><given-names>A</given-names></name></person-group>. <article-title>Wernicke&#x2019;s encephalopathy: new clinical settings and recent advances in diagnosis and management.</article-title> <source>Lancet Neurol</source>. <year>2007</year>;<volume>6</volume>(<issue>5</issue>):<fpage>442</fpage>&#x2013;<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/S1474-4422(07)70104-7</pub-id><pub-id pub-id-type="pmid">17434099</pub-id></mixed-citation></ref>
<ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jankowska-Kulawy</surname><given-names>A</given-names></name><name><surname>Bielarczyk</surname><given-names>H</given-names></name><name><surname>Pawel&#x2019;czyk</surname><given-names>T</given-names></name><name><surname>Wro&#x2019;blewska</surname><given-names>M</given-names></name><name><surname>Szutowicz</surname><given-names>A</given-names></name></person-group>. <article-title>Acetyl-CoA and acetylcholine metabolism in nerve terminal compartment of thiamine deficient rat brain.</article-title> <source>J Neurochem</source>. <year>2010</year>;<volume>115</volume>:<fpage>333</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.2010.06919.x</pub-id><pub-id pub-id-type="pmid">20649840</pub-id></mixed-citation></ref>
<ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osiezagha</surname><given-names>K</given-names></name><name><surname>Ali</surname><given-names>S</given-names></name><name><surname>Freeman</surname><given-names>C</given-names></name><name><surname>Barker</surname><given-names>NC</given-names></name><name><surname>Jabeen</surname><given-names>S</given-names></name><name><surname>Maitra</surname><given-names>S</given-names></name></person-group>. <article-title>Thiamine deficiency and delirium&#x2019;.</article-title> <source>Innov Clin Neurosci</source>. <year>2013</year>;<volume>10</volume>:<fpage>26</fpage>&#x2013;<lpage>32</lpage>.<pub-id pub-id-type="pmid">23696956</pub-id></mixed-citation></ref>
<ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boros</surname><given-names>LG</given-names></name><name><surname>Steinkamp</surname><given-names>MP</given-names></name><name><surname>Fleming</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>WN</given-names></name><name><surname>Cascante</surname><given-names>M</given-names></name><name><surname>Neufeld</surname><given-names>EJ</given-names></name></person-group>. <article-title>Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA).</article-title> <source>Blood</source>. <year>2003</year>;<volume>102</volume>:<fpage>3556</fpage>&#x2013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2003-05-1537</pub-id><pub-id pub-id-type="pmid">12893755</pub-id></mixed-citation></ref>
<ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhir</surname><given-names>S</given-names></name><name><surname>Tarasenko</surname><given-names>M</given-names></name><name><surname>Napoli</surname><given-names>E</given-names></name><name><surname>Giulivi</surname><given-names>C</given-names></name></person-group>. <article-title>Neurological, Psychiatric, and Biochemical Aspects of Thiamine Deficiency in Children and Adults.</article-title> <source>Front Psychiatry</source>. <year>2019</year>;<volume>10</volume>:<fpage>207</fpage>. <pub-id pub-id-type="doi">10.3389/fpsyt.2019.00207</pub-id><pub-id pub-id-type="pmid">31019473</pub-id></mixed-citation></ref>
<ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peake</surname><given-names>RW</given-names></name><name><surname>Godber</surname><given-names>I</given-names></name><name><surname>Maguire</surname><given-names>D</given-names></name></person-group>. <article-title>The effect of magnesium administration on erythrocyte transketolase activity in alcoholic patients treated with thiamine.</article-title> <source>Scott Med J</source>. <year>2013</year>;<volume>58</volume>(<issue>3</issue>):<fpage>139</fpage>&#x2013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1177/0036933013496944</pub-id><pub-id pub-id-type="pmid">23960051</pub-id></mixed-citation></ref>
<ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hern&#x00E1;ndez</surname><given-names>JA</given-names></name><name><surname>L&#x00F3;pez-S&#x00E1;nchez</surname><given-names>RC</given-names></name><name><surname>Rend&#x00F3;n-Ram&#x00ED;rez</surname><given-names>A</given-names></name></person-group>. <article-title>Lipids and Oxidative Stress Associated with Ethanol-Induced Neurological Damage.</article-title> <source>Oxid Med Cell Longev</source>. <year>2016</year>;<volume>2016</volume>:<elocation-id>1543809</elocation-id>. <pub-id pub-id-type="doi">10.1155/2016/1543809</pub-id><pub-id pub-id-type="pmid">26949445</pub-id></mixed-citation></ref>
<ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomson</surname><given-names>AD</given-names></name></person-group>. <article-title>Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of Wernicke-Korsakoff syndrome.</article-title> <source>Alcohol Alcohol Suppl</source>. <year>2000</year>;<volume>35</volume>:<fpage>2</fpage>&#x2013;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/alcalc/35.Supplement_1.2</pub-id><pub-id pub-id-type="pmid">11304071</pub-id></mixed-citation></ref>
<ref id="r43"><label>43</label><mixed-citation publication-type="web">MSD priru&#x010D;nik dijagnostike i terapije. Dostupno na: <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.msd-prirucnici.placebo.hr/msd-prirucnik/psihijatrija/lijekovi-droge-i-ovisnost/korsakoffljeva-psihoza">http://www.msd-prirucnici.placebo.hr/msd-prirucnik/psihijatrija/lijekovi-droge-i-ovisnost/korsakoffljeva-psihoza</ext-link>. Pristupljeno 25. 4. 2020.</mixed-citation></ref>
<ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanvisens</surname><given-names>A</given-names></name><name><surname>Zuluaga</surname><given-names>P</given-names></name><name><surname>Fuster</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Long-Term Mortality of Patients with an Alcohol-Related Wernicke-Korsakoff Syndrome.</article-title> <source>Alcohol Alcohol</source>. <year>2017</year>;<volume>52</volume>(<issue>4</issue>):<fpage>466</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1093/alcalc/agx013</pub-id><pub-id pub-id-type="pmid">28340112</pub-id></mixed-citation></ref>
<ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mee</surname><given-names>L</given-names></name><name><surname>Nabokina</surname><given-names>SM</given-names></name><name><surname>Sekar</surname><given-names>VT</given-names></name><name><surname>Subramanian</surname><given-names>VS</given-names></name><name><surname>Maedler</surname><given-names>K</given-names></name><name><surname>Said</surname><given-names>HM</given-names></name></person-group>. <article-title>Pancreatic beta cells and islets take up thiamin by a regulated carrier-mediated process: studies using mice and human pancreatic preparations.</article-title> <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2009</year>;<volume>297</volume>(<issue>1</issue>):<fpage>G197</fpage>&#x2013;<lpage>206</lpage>. <pub-id pub-id-type="doi">10.1152/ajpgi.00092.2009</pub-id><pub-id pub-id-type="pmid">19423748</pub-id></mixed-citation></ref>
<ref id="r46"><label>46</label><mixed-citation publication-type="web">National Institute for Health and Clinical Excellence. Nutrition support in adults Clinical guideline CG32. 2006. <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.nice.org.uk/page.aspx?o=cg032">www.nice.org.uk/page.aspx?o=cg032</ext-link>. Pristupljeno 25. 4. 2020.</mixed-citation></ref>
<ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedli</surname><given-names>N</given-names></name><name><surname>Stanga</surname><given-names>Z</given-names></name><name><surname>Culkin</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Management and prevention of refeeding syndrome in medical inpatients: An evidence-based and consensus-supported algorithm.</article-title> <source>Nutrition</source>. <year>2018</year>;<volume>47</volume>:<fpage>13</fpage>&#x2013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.nut.2017.09.007</pub-id><pub-id pub-id-type="pmid">29429529</pub-id></mixed-citation></ref>
<ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>da Silva</surname><given-names>JSV</given-names></name><name><surname>Seres</surname><given-names>DS</given-names></name><name><surname>Sabino</surname><given-names>K</given-names></name><etal/></person-group> <article-title>ASPEN Consensus Recommendations for Refeeding Syndrome</article-title> <comment>[published correction appears in Nutr Clin Pract. 2020 Jun;35(3):584&#x2013;585]</comment>. <source>Nutr Clin Pract</source>. <year>2020</year>;<volume>35</volume>(<issue>2</issue>):<fpage>178</fpage>&#x2013;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1002/ncp.10474</pub-id><pub-id pub-id-type="pmid">32115791</pub-id></mixed-citation></ref>
<ref id="r49"><label>49</label><mixed-citation publication-type="web">Salford Royal Care Organisation Intravenous fluid guideline for resuscitation and maintenance. 2018. <ext-link ext-link-type="uri" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.srft.nhs.uk/EasysiteWeb/getresource.axd?AssetID=13959&amp;type=full&amp;servicetype=Inline">https://www.srft.nhs.uk/EasysiteWeb/getresource.axd?AssetID=13959&amp;type=full&amp;servicetype=Inline</ext-link>. Pristupljeno 10. 5. 2020.</mixed-citation></ref>
<ref id="r50"><label>50</label><mixed-citation publication-type="other">Ifie E, Oyibo SO, Joshi H, Akintade O. Symptomatic hypophosphataemia after intravenous iron therapy: an underrated adverse reaction. Endocrinol Diabet Metab Case Rep 2019;2019(1):19&#x2013;0065. 3.</mixed-citation></ref>
<ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ammouri</surname><given-names>W</given-names></name><name><surname>Harmouche</surname><given-names>H</given-names></name><name><surname>Alaoui</surname><given-names>M</given-names></name><name><surname>Tazi</surname><given-names>ZM</given-names></name><name><surname>Maamar</surname><given-names>MM</given-names></name><name><surname>Adnaoui</surname><given-names>M</given-names></name></person-group>. <article-title>Gayet &#x2013;Wernicke encephalopathy in non alcoholic patients: A serious Complication.</article-title> <source>J Rare Dis Res Treat</source>. <year>2016</year>;<volume>1</volume>(<issue>2</issue>):<fpage>59</fpage>&#x2013;<lpage>63</lpage>. <pub-id pub-id-type="doi">10.29245/2572-9411/2016/2.1037</pub-id></mixed-citation></ref>
</ref-list>
</back>
</article>
